Chest:比较有/无哮喘老年人以及年轻患者的临床、生理和炎症特征。

2017-09-26 fengxiangxin MedSci原创

哮喘在老年人中似乎以一种特殊的表现形式存在,但其具体特征还有待进一步研究。

哮喘在老年人中似乎以一种特殊的表现形式存在,但其具体特征还有待进一步研究。

在这项前瞻性观察性研究中,研究者旨在评估老年人哮喘的多方面因素。

在年轻的(18岁至35岁)轻至中度哮喘患者和有(轻至中度)/没有哮喘的老年人(年龄≥60年)中,研究者比较了他们的哮喘控制、医疗保健和药物使用情况、肺功能、气道及全身炎症标志物和治疗依从性。

每个组招募了50名受试者。研究中发现,相比年轻哮喘患者和老年非哮喘患者,老年哮喘患者表现出更明显的气道梗阻。除此之外,相比年轻哮喘患者,虽然老年哮喘组与之有相似的气道反应性、医疗保健情况、吸入糖皮质激素剂量和治疗依从性,但也存在较差的哮喘控制,这主要与FEV1降低有关。

相比年轻哮喘患者,老年受试者的全身炎症反应和支气管上皮功能紊乱的一些指标升高。无论在年轻哮喘组和老年哮喘组,血嗜酸性粒细胞水平均较高,特别是在老年哮喘组。痰中性粒细胞在老年受试者中均增加。相比其他两组,痰嗜酸性粒细胞在老年哮喘组中增加。

老年哮喘表现为除了全身炎症反应之外与气道阻塞和混合性气道炎症相关的特异性表型。

原始出处:

Boulet LP, Robitaille C, Deschesnes F.et al.Comparative clinical, physiological and inflammatory characteristics of elderly subjects with or without asthma and young asthmatics.Chest. 2017 Sep 20. pii: S0012-3692(17)32756-3. doi: 10.1016/j.chest.2017.09.019.

本文系梅斯医学(MEDSCI)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929413, encodeId=89f419294130e, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Feb 12 11:15:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050852, encodeId=3eb7205085269, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 20 04:15:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525690, encodeId=27061525690c1, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Thu Sep 28 05:15:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247995, encodeId=843724e99533, content=感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Tue Sep 26 23:24:44 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247902, encodeId=701024e902ad, content=学习了.涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Tue Sep 26 14:30:39 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2018-02-12 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929413, encodeId=89f419294130e, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Feb 12 11:15:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050852, encodeId=3eb7205085269, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 20 04:15:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525690, encodeId=27061525690c1, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Thu Sep 28 05:15:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247995, encodeId=843724e99533, content=感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Tue Sep 26 23:24:44 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247902, encodeId=701024e902ad, content=学习了.涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Tue Sep 26 14:30:39 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929413, encodeId=89f419294130e, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Feb 12 11:15:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050852, encodeId=3eb7205085269, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 20 04:15:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525690, encodeId=27061525690c1, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Thu Sep 28 05:15:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247995, encodeId=843724e99533, content=感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Tue Sep 26 23:24:44 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247902, encodeId=701024e902ad, content=学习了.涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Tue Sep 26 14:30:39 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929413, encodeId=89f419294130e, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Feb 12 11:15:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050852, encodeId=3eb7205085269, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 20 04:15:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525690, encodeId=27061525690c1, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Thu Sep 28 05:15:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247995, encodeId=843724e99533, content=感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Tue Sep 26 23:24:44 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247902, encodeId=701024e902ad, content=学习了.涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Tue Sep 26 14:30:39 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-26 fengxiangxin301

    感谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1929413, encodeId=89f419294130e, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Feb 12 11:15:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050852, encodeId=3eb7205085269, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 20 04:15:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525690, encodeId=27061525690c1, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Thu Sep 28 05:15:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247995, encodeId=843724e99533, content=感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRr63iayTjay9otQ2yDAmbravgszHBxSLHIJpTZ8uNAiaa87bfqeDpEPTUicdBhBlf5yABuAj1OwClO4/0, createdBy=c3622063904, createdName=fengxiangxin301, createdTime=Tue Sep 26 23:24:44 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247902, encodeId=701024e902ad, content=学习了.涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Tue Sep 26 14:30:39 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-26 王秀

    学习了.涨知识了!

    0

相关资讯

J Am Soc Nephrol:研究发现,呼吸脏空气会伤害肾脏,导致心脏病、中风、癌症、哮喘和慢性阻塞性肺疾病

外空气污染长期以来与主要的健康状况有关,如心脏病、中风、癌症、哮喘和慢性阻塞性肺疾病。根据圣路易斯华盛顿大学医学院和退伍军人事务部圣路易斯卫生保健系统的研究,现在一项新的研究将肾脏疾病列入名单。

CTS全国呼吸病学学术会议:应颂敏:哮喘靶向治疗研究进展

在中华医学会呼吸病学年会-2017第十八次全国呼吸病学学术会议上,浙江大学呼吸疾病研究所/浙江大学医学院附属第二医院应颂敏教授总结了重度哮喘的靶向治疗方案,包括已经应用于临床的单克隆抗体及其团队近期发现的BCL2抑制剂ABT-737/199。

Lancet:糠酸氟替卡松和维兰特罗用于症状性哮喘的维持治疗

研究认为对于症状性哮喘维持治疗患者,每日吸入1次糠酸氟替卡松和维兰特罗可显著改善哮喘控制且不增加严重不良事件风险

Eur Respir J:哮喘儿童发生严重的神经精神ADRs 孟鲁司特风险高?

2017年8月,发表在《Eur Respir J》的一项由加拿大科学家进行的回顾性队列研究,考察了孟鲁司特初始治疗特导致哮喘儿童发生神经精神药物不良反应(ADRs)的情况,并确定孟鲁司特比吸入糖皮质激素(ICS)发生ADRs的风险更高。

Resp Med:改善哮喘和COPD的吸入技术能节省医疗费用

对于哮喘和慢性阻塞性肺疾病(COPD)的管理,较差的吸入技术或造成较差的疾病控制和较高的疾病管理成本。2017年8月,发表在《Respir Med.》的一项研究通过在德国、意大利、瑞典和英国开发了一种模型,评估哮喘和COPD患者改善吸入技术对意外医疗费用的潜在影响。

上-下气道慢性炎症性疾病联合诊疗与管理专家共识

上-下气道慢性炎症性疾病是指炎症累及上和(或)下气道的慢性疾病,其中包括:(1)以上气道为主的疾病:如变应性鼻炎(AR)、非变应性鼻炎(NAR)、慢性鼻-鼻窦炎(CRS)、上气道咳嗽综合征(UACS)、鼻息肉病、腺样体肥大等;(2)以下气道为主的疾病:如支气管哮喘(简称哮喘)、支气管扩张症(简称支扩)、慢性阻塞性肺疾病(简称慢阻肺)、慢性咳嗽、弥漫性泛细支气管炎(DPB);(3)上-下气道炎症并存